Explore the categories so you can find more about your search.
Categorie > Arthritis
MabThera(rituximab) Is More Effective In Treating Rheumatoid Arthritis Than Switching Patients To A Second Anti-TNF
Categorie : ArthritisNew data1 presented at the European League Against Rheumatism (EULAR) annual meeting revealed that when rheumatoid arthritis (RA) patients do not respond to a TNF inhibitor, a commonly used class of drugs in RA, it is more effective to treat them with MabThera (rituximab), than to use a second TNF i ...
read more 
Thu Jun 2008
New Data Reveals Actemra Is The First And Only Biologic Drug To Show Superiority Over Current Standard Of Care In Rheumatoid Arthritis
Categorie : ArthritisThe novel rheumatoid arthritis drug Actemra (tocilizumab) has shown superiority over the current standard of care, methotrexate (MTX), by achieving a greater reduction of signs and symptoms (e.g. swollen and tender joints) at 6 months in patients suffering from rheumatoid arthritis.1 This positive o ...
read more Thu Jun 2008
ACTEMRA(R) (tocilizumab) Significantly Reduces Rheumatoid Arthritis Signs And Symptoms Regardless Of Previous Therapy In Two New Global Studies
Categorie : ArthritisPatients who suffer the chronic and debilitating effects of rheumatoid arthritis (RA) -- despite treatment with current therapies -- achieved significant improvements in signs and symptoms when treated with Roche's ACTEMRA(R) (tocilizumab) alone or in combination with methotrexate compar ...
read more Thu Jun 2008
Patients Taking Cymbalta(R) Reported Reduced Pain Severity Of Osteoarthritis Of The Knee In New Study
Categorie : ArthritisNew data suggest that patients with osteoarthritis pain of the knee treated with 60 mg and 120 mg Cymbalta (duloxetine HCl) once daily experienced significant pain reduction. Patients taking duloxetine reported significant pain improvement compared to placebo within the first week of treatment th ...
read more Thu Jun 2008
Biogen Idec's Baminercept Alfa Shows Promise In Patients With Rheumatoid Arthritis
Categorie : ArthritisBiogen Idec presented data on baminercept alfa (BG9924, LTßR-Ig), the first dual-mechanism, lymphotoxin-ß; (LT-ß;) and LIGHT pathway inhibitor in development for the treatment of autoimmune diseases, including rheumatoid arthritis (RA), during the 2008 European League Against Rheumatism (EULAR) A ...
read more Thu Jun 2008
Novel DNA Microarray Chip Predicts Functional Impairment And Remission In Rheumatoid Arthritis
Categorie : ArthritisA new DNA microarray chip can predict severe disability and remission in patients with rheumatoid arthritis (RA), as presented at EULAR 2008, the Annual Congress of the European League Against Rheumatism in Paris, France. The chip (called the 'ARTchip') has yielded two clinical-genetic models of RA ...
read more Thu Jun 2008
Oily Fish Can Protect Against RA, But Smoking And Psychosocial Stress Increase Its Risk
Categorie : ArthritisResults from the EIRA studyNew data presented at EULAR 2008, the Annual Congress of the European League Against Rheumatism in Paris, France, show that intake of oily fish is associated with a reduced risk of developing rheumatoid arthritis (RA), whereas psychosocial work stress and smoking can incre ...
read more Thu Jun 2008
In Risk Of Severe Cardiovascular Events, Rheumatoid Arthritis Factors Equal To Cardiovascular Factors
Categorie : ArthritisCertain cardiovascular disease (CVD) risk factors and rheumatoid arthritis (RA) disease factors have a similar effect on an RA patient's risk of experiencing myocardial infarction (MI) or stroke, according to a new study presented at EULAR 2008, the Annual Congress of the European League Against Rhe ...
read more Thu Jun 2008
Rheumatoid Arthritis Is A Risk Factor For Cardiovascular Disease
Categorie : ArthritisThe risk of cardiovascular disease (CVD) for people with rheumatoid arthritis (RA) has been found to be comparable to the risk of CVD in people with type 2 diabetes, according to the conclusions of two studies presented at EULAR 2008, the Annual Congress of the European League Against Rheumatism in ...
read more Thu Jun 2008
Specific Mutations In The IL2RA Gene Associated With Juvenile Idiopathic Arthritis
Categorie : ArthritisCertain single nucleotide polymorphisms (SNPs) within the interleukin 2 receptor alpha (IL2RA) gene region are shown to be associated with juvenile idiopathic arthritis (JIA), according to a new study of two independent cohorts presented at EULAR 2008, the Annual Congress of the European League Agai ...
read more Thu Jun 2008
Array BioPharma Presents Additional Positive Phase 1 Results In Two Programs At The 2008 Annual European Congress Of Rheumatology
Categorie : ArthritisArray BioPharma Inc. (Nasdaq: ARRY) announced that its Chief Medical Officer, John Yates, M.D., presented additional positive results from a Phase 1 clinical trial evaluating the pharmacokinetic and pharmacodynamic activity of ARRY-162, a novel small molecule MEK inhibitor, at the 2008 Annual Europe ...
read more Thu Jun 2008
Novel PEGylated Anti-TNF Drug Cimzia Is First To Demonstrate X-ray Proof Of Significant Early Joint Protection In Rheumatoid Arthritis
Categorie : ArthritisThe first PEGylated, Fc-free, anti-tumour necrosis factor (TNF) alpha agent Cimzia (certolizumab pegol), in development for rheumatoid arthritis (RA) as an add-on therapy to methotrexate (MTX), has demonstrated X-ray evidence of ability to protect joints from structural damage at an unprecedented ea ...
read more Thu Jun 2008
Abatacept And Infliximab Improve Clinical Response Over Time In Methotrexate-Refractory RA Patients
Categorie : ArthritisResults from the ATTEST TrialNew data presented at EULAR 2008, the Annual Congress of the European League Against Rheumatism in Paris, France, show that over half of rheumatoid arthritis patients resistant to methotrexate monotherapy improved when either abatacept or infliximab were added to their m ...
read more Thu Jun 2008
Risk Of Rheumatoid Arthritis And Juvenile Idiopathic Arthritis Increased By Early Life Infections
Categorie : ArthritisInfections during the first year of life are a marker of increased risk of developing specific types of arthritis later in life, according to new research from Sweden presented at EULAR 2008, the Annual Congress of the European League Against Rheumatism in Paris, France. ...
read more Thu Jun 2008
In RA And Other Types Of Inflammatory Rheumatic Disease CV Risk Management Should Be Mandatory
Categorie : ArthritisEULAR Task Force recommendations suggest inflammation may be the key to heightened cardiovascular risksRheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA) patients should undergo compulsory cardiovascular (CV) risk management and existing CV ris ...
read more Thu Jun 2008
RA Patient Priorities And Motivators For Clinical Trial Involvement
Categorie : ArthritisTwo new initiatives designed to improve the management of rheumatoid arthritis through patient participation were presented at EULAR 2008, the Annual Congress of the European League Against Rheumatism in Paris, France. ...
read more Thu Jun 2008
30 Percent RA Patients Refractory To Anti-TNFs Achieve Disease Remission With Tocilizumab Plus Metho
Categorie : ArthritisResults of the RADIATE studyTocilizumab plus methotrexate showed significant clinical improvements in efficacy and safety in patients with moderate to severe rheumatoid arthritis (RA), who had not adequately responded to anti-tumour necrosis factor (anti-TNF) therapy, according to a new study presen ...
read more Thu Jun 2008
Joint Distraction Promotes Structural Repair In Patients With Severe Knee Osteoarthritis
Categorie : ArthritisJoint distraction (the use of a surgical frame around a degenerated joint to strengthen and promote repair) promotes cartilage repair in severe end stage osteoarthritis (OA) of the knee, as demonstrated for the first time by data presented at EULAR 2008, the Annual Congress of the European League A ...
read more Thu Jun 2008
Cimzia® Is The First Anti-TNF Shown To Inhibit Progression Of Joint Damage As Early As 16 Weeks In Rheumatoid Arthritis
Categorie : ArthritisUCB has announced new data showing that Cimzia® (certolizumab pegol), the only PEGylated, Fc-Free anti-TNF (Tumor Necrosis Factor), combined with methotrexate (MTX), significantly inhibits progression of joint damage in patients with active rheumatoid arthritis (RA) as early as 16 weeks after the s ...
read more Thu Jun 2008
Joint Damage Is Inhibited With Enbrel® (Etanercept) Plus Methotrexate In Patients With Early Active Rheumatoid Arthritis
Categorie : ArthritisData presented recently show that 80% of patients with early active rheumatoid arthritis achieved radiographic remission (or non-progression defined as a change in TSS≤0.5) at one year when treated with Enbrel (etanercept) and methotrexate, compared to 59% when treated with methotrexate alone1. ...
read more Thu Jun 2008
Custom Search
